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Abstract
Introduction and hypothesis Hysterectomy is often part of
pelvic organ prolapse repair. However, this may offer no
benefit when compared to uterine preservation. We aimed to
prospectively evaluate a minimally invasive bilateral
sacrospinous hysteropexy using polypropylene mesh. We hy-
pothesized that anatomic success and patient satisfaction can
be achieved with this technique.
Methods Women with uterovaginal prolapse desiring surgery
who had completed childbearing were enrolled. Preoperative
assessment included standardized prolapse examination and
validated symptom and pain scale questionnaires. Women
with prior pelvic organ prolapse repair or any contraindication
to uterine preservation were excluded. Data including demo-
graphic, operative and postoperative information was collect-
ed on patients for 1 year following surgery. Continuous vari-
ables are summarized as means (standard deviation) and cat-
egorical variables are summarized as frequencies and percent-
ages. A mixed-effects model was used to evaluate the changes
in questionnaire scores and outcomes at 6 months and
12 months after surgery with random effects accounting for
the center effect with adjustment for age.
Results The study group comprised 99 women from three
female pelvic medicine and reconstructive surgery
(urogynecology) centers. The average age of the participants
was 67.0 years (11.32 years), BMI 26.04 kg/m2 (3.56 kg/m2),
and the majority were multiparous (98.9 %) and menopausal
(90.9 %). Overall success at 12 months, as measured by
composite outcome was 97.7 % (with the Ba point as the
anatomic landmark) and 96.6 % (with the C point as the
anatomic landmark). The overall exposure rate was 6.52 %
and reoperation rate was 7.53 %. All subjective questionnaire
scores and anatomic outcomes had improved at 12 months.
Conclusions Sacrospinous hysteropexy using a minimally
invasive polypropylene mesh kit is an effective and safe
technique for addressing uterovaginal prolapse as an alterna-
tive to hysterectomy at the time of pelvic reconstructive
surgery.
Keywords Hysteropexy . Pelvic organ prolapse .
Polypropylenemesh . Surgery
Introduction
Minimally invasive surgical techniques are being applied to an
ever widening array of conditions that previously required
major surgical intervention. Alternatives to hysterectomy exist
for many bothersome pelvic complaints such as endometrial
ablation for menorrhagia and vascular embolization for fi-
broids. Uterovaginal prolapse is the primary indication for
the majority of vaginal hysterectomies performed in the US.
Of the more than 117,000 benign vaginal hysterectomies,
44 % were done for prolapse [1]. Although hysterectomy
has often been performed reflexively during prolapse surgery
there is a growing belief that this strategy may, for some
women, offer no specific benefit when compared to newer
minimally invasive alternatives.
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The aims of this multicenter study were to evaluate ana-
tomic success, patient satisfaction, condition-specific quality
of life, morbidity, and recuperation after minimally invasive
sacrospinous hysteropexy in women presenting with uterine
prolapseof stage II or more. The primary aim was to evaluate
the success of the sacrospinous hysteropexy procedure using a
composite measure of subjective and objective outcomes. The
secondary aims were to determine patient satisfaction, quality
of life, morbidity, and recuperation. The procedure was per-
formed in women electing to undergo surgical repair of their
prolapse using a uterus-sparing approach, and was evaluated
using standardized measures and validated questionnaires in
three major female pelvic medicine and reconstructive surgery
(urogynecology) referral centers. We wanted to evaluate
whether this technique should be considered an initial ap-
proach in the surgical treatment algorithm for uterine prolapse.
Materials and methods
After IRB approval at all institutions, subjects were recruited
from three established referral centers for urogynecology and
reconstructive pelvic surgery: (1) NorthShore University
HealthSystem, Evanston, IL, (2) Atlantic Health System Di-
vision of Urogynecology, Morristown, NJ, and (3) Boston
Urogynecology Associates, Cambridge, MA. Logistical oper-
ations and data analysis were managed at the NorthShore site.
The sample comprised 100 women with uterine prolapse
electing to undergo reconstructive vaginal surgery for that
condition, who selected uterus-sparing prolapse repair after
being familiarized with the potential benefits and risks of the
procedure and signing appropriate consents. Multichannel
urodynamic testing was performed within 6 months prior to
study enrollment in all patients with pelvic prolapse of stage II
or more and/or urinary incontinence symptoms. Women were
excluded if they had a history of previous vaginal, abdominal
or laparoscopic repair for pelvic organ prolapse; cervical
dysplasia, gynecologic cancer, undiagnosed irregular vaginal
bleeding, endometriosis, or chronic pelvic pain; language
barrier that precluded consent or questionnaire completion;
or plans for future childbearing. Information was collected on
all study patients for 1 year after their operation. The primary
outcome was a composite of objective (POP-Q points Ba less
than −1 and C less than −½ TVL) and subjective measures
(negative response to “Do you experience the feeling of
bulging or protrusion in the vaginal area?”).
Women were enrolled and preoperative data were collected
including demographic information, POP-Q measurements,
and baseline subjective questionnaire results. Surgery was
performed at each center by fellowship trained female pelvic
medicine and reconstructive surgeons. All enrolled patients
underwent hysteropexy, and anti-incontinence and other con-
comitant procedures at the surgeon’s discretion. Postoperative
data were collected. FACES pain scale measurements were
collected in the postanesthesia care unit and 24 hours after
surgery. Patients were subsequently followed at 2, 6, 12, 26,
and 52 weeks after surgery. A nonblinded pelvic examination
was performed by surgeon or fellow including POP-Q, and
validated subjective measures (Pelvic Floor Distress Invento-
ry, PFDI, and Pelvic Organ Prolapse/Urinary Incontinence
Sexual Questionnaire, PISQ) were collected at 6 and
12 months.
The study evaluated mesh-augmented sacrospinous
hysteropexy. Each sacrospinous ligament is approached
through a standard anterior vaginal incision, and the suspen-
sion procedure is performed with no entry into the peritoneal
cavity. This anterior sacrospinous technique, and its anatomic
benefits, have been previously evaluated [2]. The suspension
is bilateral, thus maintaining vaginal length and width without
deviation or narrowing of the vagina as might occur with a
traditional (unilateral) sacrospinous repair. This hysteropexy
technique utilizes a commercially available, soft, polypropyl-
ene mesh (Uphold®; Boston Scientific Corporation). Polypro-
pylene mesh repairs allow surgeons to compensate for weak
tissues by enhancing scar formation and providing a perma-
nent barrier [3]. This “minimal mesh” technique interposes a
relatively small segment of soft polypropylene mesh to rein-
force the vaginal apex and adjacent cervix to the sacrospinous
ligament bilaterally, addressing the most susceptible areas for
possible recurrence. The technique is specifically designed to
eliminate placement of any excess mesh in anatomic areas
where it would offer no benefit. The procedure is performed
through a small horizontal incision in the distal anterior vag-
inal wall to eliminate overlapping of the mesh with the vaginal
suture line to minimize mesh extrusion.
Continuous variables are summarized as means (stan-
dard deviation) or median (range) where considered ap-
propriate, and categorical variables are summarized as
frequencies and percentages. The summary statistics are
presented for the whole sample and then for each center
separately. Patient demographics, preoperative physical
examination findings, preoperative subjective scores, and
perioperative and surgical data are compared across cen-
ters (Table 1). One-way ANOVA or the Kruskal-Wallis
test was used to compare continuous variables and the
Chi-squared test was used to compare categorical vari-
ables. A mixed-effects model was used to compare chang-
es from before surgery at 6 months and at 12 months with
time as fixed effect and center as random-effect taking
into account the hierarchical structure (patients nested in
centers) with age and menopause status as covariates
where appropriate. The Tukey-Kramer method was used
to adjust p values for the multiple comparisons. Statistical
analysis was performed using SAS 9.3 for Windows
(Cary, NC, USA) with p<0.05 considered as statistically
significant.
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Results
A total of 99 women were enrolled in the study across three
centers and underwent sacrospinous mesh-augmented
hysteropexy for uterovaginal prolapse. Demographic data
are presented in Table 2. The average age of the participants
was 67.0±11.32 years, BMI was 26.04±3.56kg/m2, and the
majority were multiparous 98 (98.9 %) and menopausal 90
(90.9 %). All bilateral hysteropexy procedures were per-
formed through an anterior approach. In addition 83 % of
the enrolled participants had concomitant native tissue poste-
rior repair and 85 % had midurethral sling. Complete subjec-
tive and objective data was available for 87 % of the enrolled
participants at 12 months. The overall success rate at
12 months as measured by the composite outcome was
97.7 % (with the Ba point as the anatomic landmark) and
96.6 % (with the C point as the anatomic landmark). In
addition, calculating outcome to include any anterior, apical,
or posterior compartment POP-Q point <0 and negative re-
sponse to the PFDI question on bulge, the success rate was
97.7 %.
All POP-Qmeasurements had improved at 12 months. The
mesh extrusion rate was 6.52% across all sites. Of the patients
with polypropylene mesh exposure, many were asymptomatic
(three of seven) and required no treatment. One was managed
with successful office excision, one required surgery for ex-
cision, and two were managed with vaginal estrogen therapy.
The reoperation rate was 7.53 %. Two of six had recurrent
prolapse in the posterior compartment requiring posterior
colporrhaphy. Two patients had sling revisions. One patient
had the mesh excised and another had a vaginal hysterectomy
for recurrent apical prolapse.
All PFDI subjective questionnaire scores and anatomic
outcomes improved at both 6months and 12months (Table 3).
The PFDI scores at 12 months compared with those before
surgery were as follows: summary score −40.3±4.5
(p<.0.0001), Pelvic Organ Prolapse Distress Inventory-6
−27.1±2.1 (p<0.0001), Colorectal-Anal Distress Inventory-
8 −6.6±1.7 (p=0.0003), and Urinary Distress Inventory-6
−25.1±2.5 (p<.0.0001). The PISQ data were not robust
enough to analyze (<25 % of patients had complete PISQ data
at 12-months).
Discussion
As specialists in recent years have begun to more strongly
focus on uterus-preserving techniques, it has become more
widely acknowledged that removing the uterus may not be
necessary or beneficial for prolapse without intrauterine pa-
thology. It has been proposed that uterus-sparing prolapse
repair may provide several potential advantages including
avoidance of vaginal shortening following hysterectomy with
possible sexual dysfunction, reduced dissection and nerve
trauma, and reduced disruption of connective tissues along
the vaginal apex including the uterosacral cardinal ligament
complex and paracervical ring. These structures are thought to
contribute to maintenance of normal pelvic support, and leav-
ing them intact may help prevent recurrent vaginal vault
prolapse and/or enterocele.
From the patient perspective, across the age spectrum,
uterus-sparing surgery is an attractive alternative to a tradi-
tional hysterectomy-based repair. Many women with
uterovaginal prolapse avoid or delay an operation because
they wish to avoid hysterectomy because of its potentially
negative impact on their quality of life. In some women the
desire to avoid hysterectomy relates to a reluctance to give up
an organ so closely associated with their femininity and re-
productive health. Others may have uncertain plans for possi-
ble future childbearing, concern about the invasiveness of the
procedure, recuperation, or fear of diminished sexual function.
Uterus-sparing prolapse techniques therefore have the poten-
tial to provide both physical and psychological benefits to
many women.
Prior observational studies have suggested that
sacrospinous hysteropexy is a safe and effective alternative
to hysterectomy, with low morbidity and good patient satis-
faction. These studies have generally indicated more rapid
recovery than following hysterectomy, with less surgical mor-
bidity and blood loss, shorter operating time, significantly less
postoperative pain, and shorter hospital stay [4–7]. Kovac and
Cruikshank [4] found that unilateral sacrospinous hysteropexy
was associated with substantially less intraoperativemorbidity
than hysterectomy. Hefni et al. [5] compared uterine preser-
vation with hysterectomy and found equally high rates of
success (95 % vs. 96 %). Maher et al. [6] compared
sacrospinous hysteropexy with vaginal hysterectomy. At a
mean follow-up of 33 months, the rate of apical recurrence
after hysteropexy (3.6 %) was no higher than after vaginal
hysterectomy. The uterus-sparing technique was associated
with lower mean estimated blood loss (198 vs. 402 cm3),
shorter operative time (59 vs. 91 min), and equal patient
satisfaction (85 % vs. 86 %). Van Brummen et al. [7]
Table 2 Patient characteristics of the study sample combining data from
all centers
All centers (n=99) p value
Age (years) 67.02±11.32 0.0144*
BMI (kg/m2) 26.04±4.35 0.3629
Menopause (%) 90 0.0430*
Sexually active (%) 33 0.2160
Parity 2.92±1.45 0.5028
*p<0.05
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compared sacrospinous hysteropexy with vaginal hysterecto-
my, and found that hysterectomy was associated with a three-
fold higher rate of urgency urinary incontinence and overac-
tive bladder syndrome. Women undergoing hysteropexy re-
ported a quicker recovery than those undergoing hysterecto-
my, and there were no differences in anatomic outcomes or
prolapse recurrence rates. In a prospective randomized trial,
Dietz et al. compared 66 women after either vaginal hysterec-
tomy or sacrospinous hysteropexy and concluded that recov-
ery was earlier after hysteropexy, and despite a higher rate of
recurrent apical prolapse there were no differences in func-
tional outcomes or quality of life [8].
Pilot data on 33 graft-augmented hysteropexy procedures
indicated high rates of success with no detectable complications
after a follow-up of 1 year [9]. More recently, Vu et al. reported
data from the use of this procedure that indicated an anterior
apical (Aa) recurrence rate of 1.89 %, with no posterior (Ba≥
−1) or apical (C≥0) recurrences [10]. These results were com-
parable to those in women who had post-hysterectomy vault
prolapse and concomitant vaginal hysterectomy. The overall
mesh complication rate in this cohort was 2.6 % [10]. Our
findings suggest that sacrospinous hysteropexy using polypro-
pylene mesh is an efficacious option for the surgical manage-
ment of pelvic organ prolapse. Success rates with a composite
outcome after 1 year using this technique were excellent with
good anatomic and subjective results. Composite outcomes that
seek to measure success from various perspectives have recent-
ly gained favor [11]. The mesh exposure rate in this multicenter
trial of 6.5 % is in line with previously published rates but
higher than previously reported rates with this technique [10],
and this result may be more representative of anticipated results
throughout the world. Mesh exposure rates after vaginal sur-
gery augmented with mesh are in the range 3 – 16 %.
Mesh exposure rates generally vary and are in the range
3.6 – 18 %. Dwyer and O’Reilly reported a rate of 9 % [12].
Davila and Jijon estimated the rate at 10 % [13] and
Khandwala and Jayachandran reported a rate of 3.6 % [14].
Achtari et al. reported a rate of 7 % with polypropylene mesh
[15]. Gutman et al. reported a rate of 15.6 % with Prolift®
(Ethicon, Inc) [16]. The Cochrane review of surgical manage-
ment of pelvic organ prolapse in women indicates a rate of
18 % with 9 % of patients undergoing surgical correction for
mesh complications [17].
We recognize the controversy surrounding the surgical
repair of pelvic organ prolapse using transvaginal polypropyl-
ene mesh. We acknowledge that there are specific complica-
tions related to the use of vaginal mesh and each enrolled
patient was carefully counseled on the benefits and risks
associated with a polypropylene mesh repair. These potential
complications need to be seriously considered by both physi-
cian and patient. Our experience suggests that when surgeons
are properly trained and patients are appropriately selected
there are minimal related complications.
The study had several strengths, including the prospective,
multicenter design. The presentation of the primary outcome
as a composite of objective and subjective measures helps
define success in anatomic and clinically relevant ways that
may be more important to the patient.
Table 3 POP-Q measurements and PFDI scores from before surgery to 6 months and 12 months after surgery
6 months 12 months
Mean±SE 95 % confidence Interval p value Mean±SE 95 % confidence Interval p value
POP-Q points
Aa −3.53±0.16 (−3.91, −3.14) <0.0001* −3.49±0.15 (−3.86, −3.11) <0.0001*
Ba −4.24±0.20 (−4.73, 3.75) <0.0001* −4.19±0.20 (−4.67, −3.72 ) <0.0001*
C −5.94±0.38 (−6.85, −5.03) <0.0001* −5.90±0.37 (−6.80, −5.01) <0.0001*
Gh −1.25±0.13 (−1.58, −0.92) <0.0001* −1.23±0.13 (−1.55, −0.90) <0.0001*
pb 0.56±0.09 (0.33, 0.78) <0.0001* 0.51±0.08 (0.30, 0.72) <0.0001*
tvl 0.07±0.14 (−0.26, 0.40) 0.8611 0.06±0.13 (−0.27, 0.38) 0.9102
Ap −1.62±0.16 (−2.01, 1.22) <0.0001* −1.51±0.16 (−1.89, −1.12) <0.0001*
Bp −1.81±0.19 (−2.28, −1.35) <0.0001* −1.79±0.19 (−2.25, −1.34) <0.0001*
D −4.84±0.37 (−5.72, −3.97) <0.0001* −4.70±0.36 (−5.57, −3.82) <0.0001*
PFDI summary score −43.47±4.59 (−54.35, −32.58) <0.0001* −40.27±4.54 (−51.03, −29.51) <0.0001*
POPDI-6 −28.00±2.07 (−32.93, −23.08) <0.0001* −27.08±2.05 (−31.94, −22.22) <0.0001*
CRADI-8 −7.69±1.67 (−11.64, −3.73) <0.0001* −6.55±1.65 (−10.47, −2.64) 0.0003*
UDI-6 −24.28±2.39 (−29.95, −18.62) <0.0001* −25.12±2.47 (−30.74, −19.50) <0.0001*
PFDI Pelvic Floor Distress Inventory, POPDI Pelvic Organ Prolapse Distress Inventory, CRADI Colorectal-Anal Distress Inventory, UDI Urinary
Distress Inventory
*p<0.05
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The limitations of the study include a design without a
comparison arm or specific power calculations to enhance
statistical robustness. Another limitation was relatively short-
term results, with lack of follow up beyond 12 months. Ex-
aminations were not universally completed by a third party
and this was a potential source of bias. Our study population
was primarily Caucasian, relatively homogeneous, and lacked
racial diversity. Although a multicenter study enrollment
among sites was not consistent.
In conclusion, sacrospinous hysteropexy using a minimally
invasive polypropylene mesh kit was found to be an effective
and safe technique for addressing uterine prolapse as an
alternative to hysterectomy at the time of pelvic reconstructive
surgery when assessed with a composite outcome.
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